EBS Q1 2021 Earnings — Emergent BioSolutions Inc. Revenue & Financial Results | Market Cap Arena

EBSEmergent BioSolutions Inc.

$446M

Q1 2021 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$343M+78.2% YoY

Gross Profit

$192M56.1% margin

Operating Income

$95M27.8% margin

Net Income

$70M20.3% margin

EPS (Diluted)

$1.28

QoQ Revenue Growth

-41.2%

Cash Flow

Operating Cash Flow

$5M

Free Cash Flow

-$51M

Stock-Based Comp.

$11M

Balance Sheet

Total Assets

$2.9B

Total Liabilities

$1.4B

Stockholders' Equity

$1.5B

Cash & Equivalents

$548M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$343M	$193M	+78.2%
Gross Profit	$192M	$74M	+161.6%
Operating Income	$95M	-$12M	+922.4%
Net Income	$70M	-$13M	+657.6%

Revenue Segments

Contract Development And Manufacturing

$184M54%

Product

$138M40%

Contracts and Grants

$21M6%

Geographic Segments

UNITED STATES

$174M51%

Non-US

$169M49%